Skip to main content
Erschienen in: Angiogenesis 1/2009

01.03.2009 | Original Paper

A comparative study on the anti-angiogenic effects of DNA-damaging and cytoskeletal-disrupting agents

Erschienen in: Angiogenesis | Ausgabe 1/2009

Einloggen, um Zugang zu erhalten

Abstract

The discovery of molecules with anti-angiogenic properties has led to promising new strategies for the treatment of diseases characterized by excessive new vessel growth, such as cancer and haemangioma. We have assessed the effects of DNA-damaging and cytoskeletal-disrupting agents in vitro on several endothelial cell functions. We report that bleomycin, mitomycin C and cytoskeletal-disrupting drugs (2-methoxyestradiol, taxol, vincristine, vinblastine, colchicine, nocodazole, and cytochalasin D) exhibit anti-angiogenic activities of varying potency. Bleomycin and the various cytoskeletal-disrupting drugs inhibited endothelial cell migration, while mitomycin C had a marginal effect. Both DNA-damaging and cytoskeletal-disrupting drugs decreased endothelial cell growth in a dose-dependent manner, and this was accompanied by the induction of apoptosis. The growth inhibitory and apoptotic effects of cytoskeletal-disrupting drugs were the most pronounced. We also show that both classes of drugs inhibited capillary-like tube formation in an assay of in vitro angiogenesis, with cytoskeletal-disrupting agents inhibiting in vitro angiogenesis with greater potency. A targeted approach incorporating several compounds with different mechanisms of action may be useful for the treatment of angiogenesis-dependent diseases such as hemangiomas of infancy.
Literatur
1.
Zurück zum Zitat Enjolras O (1997) Management of hemangiomas. Dermatol Nurs 9:11–17PubMed Enjolras O (1997) Management of hemangiomas. Dermatol Nurs 9:11–17PubMed
4.
Zurück zum Zitat Pepper MS (1997) Manipulating angiogenesis. From basic science to the bedside. Arterioscler Thromb Vasc Biol 17:605–919PubMed Pepper MS (1997) Manipulating angiogenesis. From basic science to the bedside. Arterioscler Thromb Vasc Biol 17:605–919PubMed
5.
Zurück zum Zitat Mulliken JB, Glowacki J (1982) Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast Reconstr Surg 69:412–420PubMedCrossRef Mulliken JB, Glowacki J (1982) Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast Reconstr Surg 69:412–420PubMedCrossRef
6.
Zurück zum Zitat Takahashi K, Mulliken JB, Kozakewich HPW, Rogers RA, Folkman J, Ezekowitz RAB (1994) Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest 93:2357–2364. doi:10.1172/JCI117241 PubMedCrossRef Takahashi K, Mulliken JB, Kozakewich HPW, Rogers RA, Folkman J, Ezekowitz RAB (1994) Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest 93:2357–2364. doi:10.​1172/​JCI117241 PubMedCrossRef
9.
10.
Zurück zum Zitat Holmgren LL, Garcia I, Jimenez B, Mandriota SJ, Borlat F, Sim BKL et al (1998) Multiple forms of angiostatin induce apoptosis in endothelial cells. Blood 92:4730–4741PubMed Holmgren LL, Garcia I, Jimenez B, Mandriota SJ, Borlat F, Sim BKL et al (1998) Multiple forms of angiostatin induce apoptosis in endothelial cells. Blood 92:4730–4741PubMed
14.
Zurück zum Zitat Klauber N, Parangi S, Flynn E et al (1997) Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 57:81–86PubMed Klauber N, Parangi S, Flynn E et al (1997) Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 57:81–86PubMed
20.
Zurück zum Zitat Mabeta P, Davis PF (2008) The mechanism of bleomycin in inducing haemangioma regression. S Afr Med J 98:538–539PubMed Mabeta P, Davis PF (2008) The mechanism of bleomycin in inducing haemangioma regression. S Afr Med J 98:538–539PubMed
23.
Zurück zum Zitat Mandriota SJ, Pepper MS (1997) Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent on endogenous basic fibroblast growth factor. J Cell Sci 110:2293–2302PubMed Mandriota SJ, Pepper MS (1997) Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent on endogenous basic fibroblast growth factor. J Cell Sci 110:2293–2302PubMed
24.
25.
Zurück zum Zitat Pepper MS, Ferrara N, Orci L, Montesano R (1992) Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 189:824–831. doi:10.1016/0006-291X(92)92277-5 PubMedCrossRef Pepper MS, Ferrara N, Orci L, Montesano R (1992) Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 189:824–831. doi:10.​1016/​0006-291X(92)92277-5 PubMedCrossRef
Metadaten
Titel
A comparative study on the anti-angiogenic effects of DNA-damaging and cytoskeletal-disrupting agents
Publikationsdatum
01.03.2009
Erschienen in
Angiogenesis / Ausgabe 1/2009
Print ISSN: 0969-6970
Elektronische ISSN: 1573-7209
DOI
https://doi.org/10.1007/s10456-009-9134-8

Weitere Artikel der Ausgabe 1/2009

Angiogenesis 1/2009 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.